retatrutide clinical trial results 2024 Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide produces up to 30.3%

Nausea and Vomiting Up to 50% of patients experience nausea, especially in the first few weeks

Properly stored at refrigerated temperatures and shielded from light, a reconstituted vial generally maintains stability for roughly 24 weeks before degradation becomes a concern, while the unmixed, lyophilized powder can remain stable for months when kept frozen and undisturbed

Your provider will evaluate your risk and may recommend proactive bone support strategies, including calcium and vitamin D supplementation

This market has grown explosively, projected to expand from 4.1 billion dollars to 13 billion by 2035

Distribution of FcRn across species and tissues

doi: 10.1073/pnas.2014879117 233 ChoeHJChoYM